Jung, BH Park, YH Park, J Chung, BC 2024-01-21T18:09:56Z 2024-01-21T18:09:56Z 2021-09-05 1997-08 0253-6269 https://pubs.kist.re.kr/handle/201004/143683 Metabolite identification and urinary and biliary excretion of the new fluoroquinolone antibacterial agent DW116 [1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, hydrochloride] after oral administration have been studied in Sprague-Dawley rats. The excretion kinetics were monoexponential. Most of the drug was eliminated via the hepatic and renal routes. Mean renal clearance of DW116 was 73.4 ml/hr/kg and mean biliary clearance was 83.8 ml/hr/kg. The major metabolite excreted in the bile was identified as the glucuronide ester of the parent drug using base-hydrolysis of the conjugate metabolite followed by co-HPLC with standard compound, F-19-NMR and LC-MS methods. The glucuronide conjugate was also found in urine. The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6+/-2.7% and 36.4+/-1.8% of the administered dose and the corresponding biliary recoveries were 14.4+/-5.5% and 37.0+/-7.6%, respectively. English PHARMACEUTICAL SOCIETY KOREA PHARMACOKINETICS Metabolism and excretion study of DW116, a new fluoroquinolone, in rats Article 10.1007/BF02976200 1 ARCHIVES OF PHARMACAL RESEARCH, v.20, no.4, pp.358 - 362 ARCHIVES OF PHARMACAL RESEARCH 20 4 358 362 scie scopus A1997XT70700011 2-s2.0-0345419173 Chemistry, Medicinal Pharmacology & Pharmacy Pharmacology & Pharmacy Article PHARMACOKINETICS fluoroquinolone DW116 metabolism pharmacokinetics